Recent Investment Analysts’ Ratings Changes for vTv Therapeutics (VTVT)

vTv Therapeutics (NASDAQ: VTVT) recently received a number of ratings updates from brokerages and research firms:

• 3/14/2026 – vTv Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/12/2026 – vTv Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $44.00 price target on the stock.
• 3/12/2026 – vTv Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $44.00 price target on the stock.
• 3/11/2026 – vTv Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $49.00 price target on the stock.
• 1/27/2026 – vTv Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $49.00 price target on the stock, up from $40.00.
• 1/22/2026 – vTv Therapeutics is now covered by Roth Mkm. They set a “buy” rating and a $58.00 price target on the stock.
• 1/22/2026 – vTv Therapeutics is now covered by Roth Mkm. They set a “buy” rating and a $58.00 price target on the stock.

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.